May 29, 2018 09:03 AM EDT

After sinking $300M into SF fund last year, Hong Kong conglomerate launches $100M arm in Shanghai

Brittany Meiling

Last year, Chinese investor Nan Fung Group — once a textiles maker, now a real estate and life sciences investment conglomerate — was the solo backer of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After sinking $300M into SF fund last year, Hong Kong conglomerate launches $100M arm in Shanghai

Brittany Meiling

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Af­ter sink­ing $300M in­to SF fund last year, Hong Kong con­glom­er­ate launch­es $100M arm in Shang­hai

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

After sinking $300M into SF fund last year, Hong Kong conglomerate launches $100M arm in Shanghai